| KEDRION |
KEDRION |
92%
|
Sales to Kedrion accounted for approximately 30%, 31% and 23% of our total revenues in the years ended December 31, 2025, 2024 and 2023, respectively. |
| BAX |
Baxter International Inc. |
85%
|
Reciprocal relationship from BAX graph: Reciprocal relationship from KMDA graph: ck Exchange, which spun-off from Baxter International Inc. ("Baxter") on July 1, 2015. The partnership agreement was o… |
| BAXALTA-US-INC |
BAXALTA-US-INC |
85%
|
er assigned all its rights under the collaboration agreement to Baxalta US Inc. (“Baxalta”) which was acquired during 2016 by Shire plc. (“Shire”), which is now part of Takeda (“Takeda” and in these … |
| BAXTER-HEALTHCARE-CORPORATION |
BAXTER-HEALTHCARE-CORPORATION |
85%
|
2010, the Company entered into a 30 -year collaboration agreement with Baxter Healthcare Corporation (“Baxter”) with respect for granting of the distribution rights for GLASSIA. During 2015, Baxter a… |
| BIOTEST-AG |
BIOTEST-AG |
85%
|
/or at a reasonable cost, would have a material adverse effect on our business, financial condition and results of operations. Sales of products supplied by Biotest AG, Kedrion, Chiesi Farmaceutici S… |
| CSL-BEHRING-LTD |
CSL-BEHRING-LTD |
85%
|
as our future results of operations and profitability. CYTOGAM is manufactured at our facility in Beit Kama, Israel since 2023. To manufacture CYTOGAM, we engaged Prothya Biosolutions Belgium (“Proth… |
| KEDRION-KEDPLASMA-LLC |
KEDRION-KEDPLASMA-LLC |
85%
|
31, 2033. We currently also purchase from a subsidiary of Kedrion, KedPlasma LLC (“Kedplasma”), a large portion of the hyper-immune plasma, which is used for the production of KEDRAB/KAMRAB. See “— W… |
| ALVO |
Alvotech |
72%
|
Reciprocal relationship from ALVO graph: Reciprocal relationship from KMDA graph: us with a prior notice of non-renewal of the agreement, prior any automatic renewal term. 52 Other Products In recent… |
| ALVO |
Alvotech |
72%
|
us with a prior notice of non-renewal of the agreement, prior any automatic renewal term. 52 Other Products In recent years, we sold small quantities of Human Transferrin, which is used as a cultural… |
| BAX |
Baxter International Inc. |
72%
|
ck Exchange, which spun-off from Baxter International Inc. ("Baxter") on July 1, 2015. The partnership agreement was originally executed with Baxter. During 2015, Baxter assigned all its rights under… |
| CHKP |
Check Point Software Technologies Ltd. |
72%
|
Reciprocal relationship from CHKP graph: Reciprocal relationship from KMDA graph: they will be utilized. Deductible carryforward losses and temporary differences for which deferred tax assets have no… |
| CHKP |
Check Point Software Technologies Ltd. |
72%
|
they will be utilized. Deductible carryforward losses and temporary differences for which deferred tax assets have not been recognized are reviewed at the end of each reporting period, and a respecti… |
| GILT |
Gilat Satellite Networks Ltd. |
72%
|
they will be utilized. Deductible carryforward losses and temporary differences for which deferred tax assets have not been recognized are reviewed at the end of each reporting period, and a respecti… |
| GILT |
Gilat Satellite Networks Ltd. |
72%
|
Reciprocal relationship from GILT graph: Reciprocal relationship from KMDA graph: Reciprocal relationship from GILT graph: Reciprocal relationship from KMDA graph: Reciprocal relationship from GILT g… |
| ICL |
ICL Group Ltd |
72%
|
Reciprocal relationship from ICL graph: Reciprocal relationship from KMDA graph: Reciprocal relationship from ICL graph: Reciprocal relationship from KMDA graph: they will be utilized. Deductible car… |
| ICL |
ICL Group Ltd |
72%
|
they will be utilized. Deductible carryforward losses and temporary differences for which deferred tax assets have not been recognized are reviewed at the end of each reporting period, and a respecti… |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from KMDA graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from KMDA graph: Reciprocal relationship from JNJ grap… |
| JNJ |
Johnson & Johnson |
72%
|
al forecasts. Customers For the year ended December 31, 2015, sales to Baxalta and Kupat Holim Clalit, an Israeli healthcare provider, accounted for 37% and 15%, respectively, of our total revenues. … |
| LLY |
Eli Lilly and Company |
72%
|
Reciprocal relationship from LLY graph: Reciprocal relationship from KMDA graph: us with a prior notice of non-renewal of the agreement, prior any automatic renewal term. 52 Other Products In recent … |
| LLY |
Eli Lilly and Company |
72%
|
us with a prior notice of non-renewal of the agreement, prior any automatic renewal term. 52 Other Products In recent years, we sold small quantities of Human Transferrin, which is used as a cultural… |
| NVSEF |
Novartis AG |
72%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from KMDA graph: al forecasts. Customers For the year ended December 31, 2015, sales to Baxalta and Kupat Holim Clalit, an Israeli he… |
| NVSEF |
Novartis AG |
72%
|
al forecasts. Customers For the year ended December 31, 2015, sales to Baxalta and Kupat Holim Clalit, an Israeli healthcare provider, accounted for 37% and 15%, respectively, of our total revenues. … |
| PPBT |
Purple Biotech Ltd |
72%
|
Reciprocal relationship from PPBT graph: Reciprocal relationship from KMDA graph: they will be utilized. Deductible carryforward losses and temporary differences for which deferred tax assets have no… |
| PPBT |
Purple Biotech Ltd |
72%
|
they will be utilized. Deductible carryforward losses and temporary differences for which deferred tax assets have not been recognized are reviewed at the end of each reporting period, and a respecti… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from KMDA graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from KMDA graph: al forecasts. Customers For the y… |
| SNYNF |
Sanofi |
72%
|
al forecasts. Customers For the year ended December 31, 2015, sales to Baxalta and Kupat Holim Clalit, an Israeli healthcare provider, accounted for 37% and 15%, respectively, of our total revenues. … |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
Reciprocal relationship from TKPHF graph: Reciprocal relationship from KMDA graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from KMDA graph: Reciprocal relationship from TKPH… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
our 2020 revenues will be in the range of $132 million to $137 million, with the year-over-year growth driven by increased sales of Proprietary IgG products portfolio and Alpha-1 Antitrypsin (“AAT”) … |
| VALN |
Valneva SE |
72%
|
.G., Kedrion, Chiesi Farmaceutici S.p.A, BPL and Valneva SE, which are sold in our Distribution segment, together represented approximately 20%, 26% and 24% of our total revenues for the years ended … |
| VALN |
Valneva SE |
72%
|
Reciprocal relationship from VALN graph: Reciprocal relationship from KMDA graph: .G., Kedrion, Chiesi Farmaceutici S.p.A, BPL and Valneva SE, which are sold in our Distribution segment, together rep… |
